Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Maze Therapeutics is a clinical-stage biotechnology company dedicated to developing a new generation of precision medicines for patients with genetically defined diseases. By leveraging human genetics, functional genomics, and advanced data science, Maze aims to identify and validate novel therapeutic targets and create transformative therapies. Their focus is on translating complex genetic insights into impactful treatments, addressing significant unmet medical needs in areas like Pompe disease, chronic kidney disease, and other rare conditions.
The headquarters serves as the central hub for Maze Therapeutics' research and development, clinical operations, corporate strategy, and administrative functions.
Located in a prominent biotechnology hub, the facility likely features state-of-the-art laboratory spaces, modern office environments, and collaborative workspaces designed to foster innovation.
Maze Therapeutics fosters a work culture centered on scientific rigor, collaboration, patient-centricity, and innovation. Employees (Mazers) are encouraged to be bold, pursue cutting-edge science, and work together to solve complex biological problems.
The South San Francisco headquarters is strategically significant due to its proximity to a rich ecosystem of academic institutions, research organizations, and other biotech companies, facilitating collaborations and talent acquisition.
While headquartered in South San Francisco, Maze Therapeutics conducts clinical trials and engages in research collaborations that may span multiple countries. Their commitment to addressing genetically defined diseases necessitates a global outlook in terms of patient populations, research partnerships, and potential future market access.
171 Oyster Point Blvd, Suite 300
South San Francisco
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Maze Therapeutics' leadership includes:
Maze Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months, Maze Therapeutics has strengthened its executive team with key appointments in finance and human resources, reflecting its continued growth and strategic development. No major executive departures have been publicly announced during this period.
Discover the tools Maze Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Maze Therapeutics likely uses a common corporate email format. Based on industry standards and available information, the primary format is often a combination of the employee's first initial and last name.
[first_initial][last]@mazetx.com
Format
jcoloma@mazetx.com
Example
85%
Success rate
Business Wire • May 7, 2024
Maze Therapeutics shared preclinical data on MZE001, an oral glycogen synthase (GYS1) inhibitor, for Pompe disease. The data demonstrated significant reductions in glycogen storage in multiple preclinical models, supporting its potential as a substrate reduction therapy....more
GlobeNewswire • April 8, 2024
Maze Therapeutics announced it would present preclinical data on its APOL1 inhibitor program for APOL1-mediated kidney disease (AMKD) at the AAN 2024 Annual Meeting, showcasing a potential new treatment avenue....more
GlobeNewswire • February 28, 2024
Maze Therapeutics initiated a Phase 1 clinical trial for MZE829, an oral mtDNA polymerase gamma (POLG) inhibitor, aimed at treating Maternally Inherited Leigh Syndrome and MELAS, two rare mitochondrial diseases with no approved therapies....more
Maze Therapeutics Press Release • September 6, 2023
Maze Therapeutics announced the appointment of Naveen Krishnan, M.D., M.Phil., as its new Chief Financial Officer. Dr. Krishnan brings extensive experience in healthcare finance and investment to the role....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Maze Therapeutics, are just a search away.